Alexis Perkins thought her OB-GYN’s office in Atlanta would be just the place to get a prescription for the type of drug that reduces a person’s risk of contracting HIV.
Poseida lines up another allogeneic CAR-T partner, allying with Astellas on solid tumors
Astellas will buy about 8.8% of Poseida Therapeutics for $25 million, and match that with a one-time payment for right of first refusal to license
August 8, 2023